Welcome to the Emerging Pathogens & Infectious Diseases Consortium
Welcome to EPIC – the Emerging Pathogens and Infectious Diseases Consortium.
EPIC brings together researchers, clinicians, and institutions across the University of Toronto and its hospital partners to advance infectious disease research and build lasting resilience against emerging threats.
This work builds on a long legacy: EPIC partners have played an integral role in infectious disease research for a century, from work that helped control diphtheria and eradicate smallpox, to today’s front-line research in antimicrobial resistance and infection control. Our collective response to COVID-19, highly pathogenic avian influenza, and mpox makes clear there’s never been a more important time to advance that work, from emerging pathogens and antimicrobial resistance to health inequities and public trust.
Building on this momentum, EPIC marshals the advanced research infrastructure and world-renowned research and training expertise of our EPIC partners to deliver an integrated, innovative response to the infectious disease challenges facing communities today and in the future.
Seven EPIC research clusters
Antimicrobial Resistance
Protecting the effectiveness of the medicines we depend on.
Chronic Infections
Addressing the long-term burden of infections that don’t resolve.
Emerging Pathogens
Detecting and responding to new and re-emerging threats before they spread.
Health Inequities
Ensuring infectious disease research and response reach everyone, equitably.
Health Systems Resilience
Building health systems that bend, not break, under infectious threats.
Misinformation, Disinformation & Public Trust
Strengthening public trust through clear, credible information.
Sepsis & Acute Respiratory Distress
Improving detection and treatment when every minute counts.
EPIC News
Putting knowledge into action: the third annual symposium on antimicrobial resistance advances our fight against AMR
December 16, 2024 By Sunitha Chari Coinciding with the World Antimicrobial Resistance (AMR) Week, the Emerging and Pandemic Infections Consortium (EPIC) once again co-hosted the third annual AMR Symposium on November 19 and 20 empowered by bioMérieux Canada and...
Pre-exposure prophylaxis has emerged as a powerful strategy to deal with HIV burden, but challenges remain: a Q&A with Rupert Kaul
Rupert Kaul is a clinician scientist whose research focuses on mucosal immunity and HIV transmission and a world leader in HIV research and medicine December 3, 2024 By Sunitha Chari December 1, 2024, marked World AIDS Day, and forty years since the discovery of the...
From surveillance to control: U of T researchers are tackling the AMR problem from all angles
From left: Véronique Taylor, Duncan Carruthers-Lay, Marcus Dillon, Viplav Agarwal, Michael Fralick November 28, 2024 By Sunitha Chari As communities around the world marked World Antimicrobial Resistance (AMR) Awareness Week from November 18 to 24, 2024 we shine the...
